Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an AI trained on real heart patients outsmart generic chatbots?

NCT ID NCT07766551

Knowledge-focused Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study aims to build a specialized AI model, called CorAI, for coronary artery disease (CAD). Researchers will collect de-identified medical data from about 640 patients with suspected or confirmed CAD to create a rich dataset. Using this data, they will develop and test CorAI to see if its recommendations align with clinical guidelines, potentially offering a new tool to support doctors' decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CorAI, a disease-specific large language model (AI) developed and evaluated using patient data
What this could lead to
If successful, this could lead to an AI tool that helps doctors make more guideline-aligned decisions for heart disease patients, potentially improving care quality.
What could go wrong
The AI model is new and untested in real-world settings. It may not perform as expected or may not generalize beyond the study's specific patient group. There is also a risk of AI errors or biases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 640 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with confirmed or suspected coronary heart disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years; * Patients with confirmed or suspected coronary heart disease; * Complete case information (including medical history, test results, imaging, follow-up records, etc.); * Consent for the use of case data for model evaluation and research analysis. Exclusion Criteria: * Cases with severe data gaps that prevent the formation of a complete clinical scenario; * Cases where the primary diagnosis is not coronary heart disease; * Cases with serious data errors or where data cannot be anonymized.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artifical intelligence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artifical intelligence Coronary heart disease (CHD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen

    Shenzhen, Guangdong, 518057, China

  • Fuwai Hospital, Chinese Academy of Medical Sciences/National Center for Cardiovascular Diseases

    Beijing, Beijing Municipality, 100037, China

  • The First Affiliated Hospital of USTC

    Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.